188 related articles for article (PubMed ID: 32726783)
21. JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors.
Irey EA; Lassiter CM; Brady NJ; Chuntova P; Wang Y; Knutson TP; Henzler C; Chaffee TS; Vogel RI; Nelson AC; Farrar MA; Schwertfeger KL
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12442-12451. PubMed ID: 31147469
[TBL] [Abstract][Full Text] [Related]
22. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer.
Portsmore S; Tran Nguyen TN; Beacham E; Neelakantan P
Br J Haematol; 2020 Aug; 190(4):525-528. PubMed ID: 32584421
[No Abstract] [Full Text] [Related]
23. Impact of JAK/STAT inhibitors on human monocyte-derived-macrophages stimulated by cigarette smoke extract and lipopolysaccharide.
Verres Y; da Silva CO; Aljebawi B; Bodin A; Barreto E; Lagente V; Victoni T
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1187-1196. PubMed ID: 35876719
[TBL] [Abstract][Full Text] [Related]
24. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy.
Satarker S; Tom AA; Shaji RA; Alosious A; Luvis M; Nampoothiri M
Postgrad Med; 2021 Jun; 133(5):489-507. PubMed ID: 33245005
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
[TBL] [Abstract][Full Text] [Related]
26. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
27. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
29. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.
Febvre-James M; Lecureur V; Fardel O
Inflamm Res; 2020 Jan; 69(1):51-62. PubMed ID: 31654094
[TBL] [Abstract][Full Text] [Related]
30. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M; Ferrada MA; Koster MJ; Barba T; Gerfaud-Valentin M; Mékinian A; Coelho H; Fossard G; Barraco F; Galicier L; Bienvenu B; Hirsch P; Vial G; Boutin AB; Galland J; Le Guenno G; Bigot A; Warrington KJ; Kermani TA; Grayson PC; Patel BA; Beck DB; Jamilloux Y; Fenaux P; Sujobert P
Blood; 2022 Aug; 140(8):927-931. PubMed ID: 35609174
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.
Caradec E; Mouren D; Zrounba M; Azoulay LD; Blandin C; Ivanoff S; Levy V; Brillet PY; Nunes H; Uzunhan Y
Respir Med Res; 2021 May; 79():100799. PubMed ID: 33242734
[No Abstract] [Full Text] [Related]
33. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
34. The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases.
Türk C; Okay M; Türk S; Temirci ES; Javad O; Aksu S; Sayınalp N; Haznedaroğlu İC
Turk J Med Sci; 2019 Apr; 49(2):661-674. PubMed ID: 30997981
[TBL] [Abstract][Full Text] [Related]
35. A potential role of ruxolitinib in leukemia.
Naqvi K; Verstovsek S; Kantarjian H; Ravandi F
Expert Opin Investig Drugs; 2011 Aug; 20(8):1159-66. PubMed ID: 21635221
[TBL] [Abstract][Full Text] [Related]
36. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
37. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
Saraceni F; Scortechini I; Mancini G; Mariani M; Federici I; Gaetani M; Barbatelli P; Minnucci ML; Bagnarelli P; Olivieri A
Transpl Infect Dis; 2021 Feb; 23(1):e13401. PubMed ID: 32629531
[TBL] [Abstract][Full Text] [Related]
38. Hematologic disorders associated with COVID-19: a review.
Rahi MS; Jindal V; Reyes SP; Gunasekaran K; Gupta R; Jaiyesimi I
Ann Hematol; 2021 Feb; 100(2):309-320. PubMed ID: 33415422
[TBL] [Abstract][Full Text] [Related]
39. Multiple Biomarker Approach to Risk Stratification in COVID-19.
Smilowitz NR; Nguy V; Aphinyanaphongs Y; Newman JD; Xia Y; Reynolds HR; Hochman JS; Fishman GI; Berger JS
Circulation; 2021 Mar; 143(13):1338-1340. PubMed ID: 33587646
[No Abstract] [Full Text] [Related]
40. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
